VGI Trugene Interpretation Software Showcased At Seville HIV/AIDS Meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA's clearance process for future versions of Visible Genetics, Inc.'s HIV drug resistance assay interpretation systems may provide a key to how the agency will review next-generation genetic tests
You may also be interested in...
ViroLogic Vying For HIV Resistance Market Advantage As Rival Mulls Merger
ViroLogic's new HIV replication assay will help drive conversion of the resistance testing market from genotype to phenotype-based tests, the firm believes
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.